Streaming issues? Report here
Aubrey Masango 1500 x 1500 2020 Aubrey Masango 1500 x 1500 2020
The Aubrey Masango Show
20:00 - 00:00
volume_up
volume_mute

The Aubrey Masango Show
20:00 - 00:00
Home
arrow_forward
Business
fiber_manual_record
Local
fiber_manual_record
Africa

'Africa breakthrough': Aspen SA to produce own branded vaccine in deal with J&J

30 November 2021 9:04 PM
Tags:
The Money Show
Aspen
Aspen Pharmacare
Bruce Whitfield
Stephen Saad
Johnson & Johnson
vaccine
COVID-19 vaccine
Aspenovax
J & J
Aspen vaccine
vaccination in Africa

Aspen will produce its vaccine under the brand name "Aspenovax". Bruce Whitfield interviews Stephen Saad, CEO of Aspen Pharmacare.
© svershinsky/123rf.com

Aspen Pharmacare is striking a deal that would allow it to manufacture the Johnson & Johnson Covid-19 vaccine under its own label, for distribution on the African continent.

Aspenovax will be manufactured in South Africa at Aspen's Gqeberha plant.

"The term of the grant of rights and supply of drug substance, subject to the signing of the definitive agreement, would be until 31 December 2026."

In conversation with Bruce Whitfield Stephen Saad (CEO of Aspen Pharmacare) describes the agreement as "a massive breakthrough for Africa".

On the continent, we import 99% of our vaccines. It's fine normally but when you have a pandemic, countries serve themselves first and when India stopped exporting we got no vaccines in Africa!

Stephen Saad, CEO - Aspen Pharmacare

The difference here for us is that we sell to the clients and we control where the product goes to. When you are simply a contract manufacturer selling to a principal, that principal determines where your product goes.

Stephen Saad, CEO - Aspen Pharmacare

This gives you 100% certainty that what we make stays in Africa.

Stephen Saad, CEO - Aspen Pharmacare

Saad explains that the only payment that goes to J & J is what Aspen pays to acquire the drug substance from them.

Our plan is to to be sustainable, to make an impact, and then to be competitive.

Stephen Saad, CEO - Aspen Pharmacare

We will be manufacturing at Gqeberha... and we are hoping to have our capacities there increased by the end of 2021... We're hoping to start as soon as we can in 2022..

Stephen Saad, CEO - Aspen Pharmacare

It would replicate the J & J [vaccine]... but it would be in Aspen's name... so we would have to get our own registration for our own brand.

Stephen Saad, CEO - Aspen Pharmacare

Listen to the audio below for more detail on Aspen's vaccine deal with J & J:


This article first appeared on CapeTalk : 'Africa breakthrough': Aspen SA to produce own branded vaccine in deal with J&J




30 November 2021 9:04 PM
Tags:
The Money Show
Aspen
Aspen Pharmacare
Bruce Whitfield
Stephen Saad
Johnson & Johnson
vaccine
COVID-19 vaccine
Aspenovax
J & J
Aspen vaccine
vaccination in Africa

More from Business

More from Local

More from Africa